273 related articles for article (PubMed ID: 7639234)
1. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
[TBL] [Abstract][Full Text] [Related]
2. The circulating common gamma chain (CD132) in inflammatory bowel disease.
Nielsen OH; Kirman I; Johnson K; Giedlin M; Ciardelli T
Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
4. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.
Ludwiczek O; Vannier E; Borggraefe I; Kaser A; Siegmund B; Dinarello CA; Tilg H
Clin Exp Immunol; 2004 Nov; 138(2):323-9. PubMed ID: 15498044
[TBL] [Abstract][Full Text] [Related]
5. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
[TBL] [Abstract][Full Text] [Related]
6. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
Mokrowiecka A; Gasiorowska A; Małecka-Panas E
Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
[TBL] [Abstract][Full Text] [Related]
8. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity.
Yosipovitch G; Shohat B; Bshara J; Wysenbeek A; Weinberger A
Isr J Med Sci; 1995 Jun; 31(6):345-8. PubMed ID: 7607852
[TBL] [Abstract][Full Text] [Related]
10. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease.
Andoh A; Tsujikawa T; Hata K; Araki Y; Kitoh K; Sasaki M; Yoshida T; Fujiyama Y
Am J Gastroenterol; 2005 Sep; 100(9):2042-8. PubMed ID: 16128950
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Bansi DS; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
[TBL] [Abstract][Full Text] [Related]
12. Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study.
Annese V; Andreoli A; Andriulli A; Dinca R; Gionchetti P; Latiano A; Lombardi G; Piepoli A; Poulain D; Sendid B; Colombel JF
Am J Gastroenterol; 2001 Aug; 96(8):2407-12. PubMed ID: 11513182
[TBL] [Abstract][Full Text] [Related]
13. Elevated thrombopoietin serum levels in patients with inflammatory bowel disease.
Kapsoritakis AN; Potamianos SP; Sfiridaki AI; Koukourakis MI; Koutroubakis IE; Roussomoustakaki MI; Manousos ON; Kouroumalis EA
Am J Gastroenterol; 2000 Dec; 95(12):3478-81. PubMed ID: 11151880
[TBL] [Abstract][Full Text] [Related]
14. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases.
Heresbach D; Alizadeh M; Dabadie A; Le Berre N; Colombel JF; Yaouanq J; Bretagne JF; Semana G
Am J Gastroenterol; 1997 Jul; 92(7):1164-9. PubMed ID: 9219791
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
16. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
17. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
[TBL] [Abstract][Full Text] [Related]
18. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
[TBL] [Abstract][Full Text] [Related]
19. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
[TBL] [Abstract][Full Text] [Related]
20. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis.
Kirman I; Nielsen OH
Am J Gastroenterol; 1996 Sep; 91(9):1789-94. PubMed ID: 8792700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
